CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 144 enrolled
Drug / intervention
RAS Prostatectomy +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05696444
NCT05696444N/AActive
CompareCT.gov

A Prospective, Multi-center, Single-arm Study of the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)

Medtronic - MITG·interventional·Posted Jan 25, 2023·Updated Nov 25, 2025

In Brief

A clinical study evaluating RAS Prostatectomy, RAS Cystectomy, and 1 other intervention for Bladder Cancer and 8 related conditions. Active but no longer recruiting, targeting 144 participants across 6 sites.

Detailed Summary

This study will evaluate the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor, Interstitial Cystitis, Congenital Abnormalities, End Stage Renal Disease, Renal Tumor, Kidney Injury
CountriesUnited States
Collaborators--

Timeline

N/AActive
20232024202520262027202820292030
First PostedJan 25, 2023
Enrollment StartDec 14, 2022
Primary CompletionOct 10, 2024
Study CompletionJan 31, 2030
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 3.4 years ago

Interventions

RAS Prostatectomydevice

Subjects indicated for Robotic Assisted Surgery (RAS) for prostatectomy will have RAS surgery using the Medtronic Hugo RAS system.

RAS Cystectomydevice

Subjects indicated for Robotic Assisted Surgery (RAS) for cystectomy will have RAS surgery using the Medtronic Hugo RAS system.

RAS Nephrectomydevice

Subjects indicated for Robotic Assisted Surgery (RAS) for nephrectomy (Radical/Partial) will have RAS surgery using the Medtronic Hugo RAS system.